Harrow, Inc. (NASDAQ:HROW - Get Free Report) insider Amir Shojaei sold 11,250 shares of the company's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $40.00, for a total transaction of $450,000.00. Following the completion of the transaction, the insider owned 11,250 shares of the company's stock, valued at $450,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Harrow Stock Performance
Shares of HROW stock opened at $39.47 on Tuesday. The stock's 50-day moving average is $41.07 and its two-hundred day moving average is $39.83. The company has a debt-to-equity ratio of 19.70, a quick ratio of 2.08 and a current ratio of 2.24. Harrow, Inc. has a 1 year low of $28.54 and a 1 year high of $54.85. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -39.47 and a beta of 0.28.
Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.28). The firm had revenue of $70.66 million during the quarter, compared to analyst estimates of $70.35 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%. Analysts predict that Harrow, Inc. will post 0.11 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Harrow in a report on Monday, July 20th. Cantor Fitzgerald decreased their price target on shares of Harrow from $91.00 to $88.00 and set an "overweight" rating for the company in a research note on Wednesday, May 13th. BTIG Research reissued a "buy" rating and set a $63.00 price objective on shares of Harrow in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Harrow from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Zacks Research cut shares of Harrow from a "hold" rating to a "strong sell" rating in a report on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $69.43.
Check Out Our Latest Stock Report on Harrow
Hedge Funds Weigh In On Harrow
Institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC lifted its stake in shares of Harrow by 13.1% in the 4th quarter. Larson Financial Group LLC now owns 2,446 shares of the company's stock worth $120,000 after acquiring an additional 284 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Harrow by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company's stock worth $505,000 after acquiring an additional 341 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company's stock worth $88,000 after purchasing an additional 369 shares in the last quarter. Captrust Financial Advisors raised its holdings in Harrow by 0.5% during the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company's stock worth $3,428,000 after purchasing an additional 376 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company's stock valued at $1,422,000 after purchasing an additional 500 shares during the period. 72.76% of the stock is owned by institutional investors and hedge funds.
About Harrow
(
Get Free Report)
Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.
Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
